Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT plus CTLA-4/PD-1 dual immunotherapy in pMMR/MSS colorectal liver metastases
ChiCTR2500105135Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in colorectal cancer (CRC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Objective tumor response rate and RTOG acute radiation injury grading. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500105135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105135.